Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases
Article in Antimicrobial Agents and Chemotherapy (March 2023)
The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.
High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production
Article in Open Forum Infectious Diseases (January 2023)
Development of nanobodies as theranostic agents against CMY-2-like class C β-lactamases
Preprint in bioRxiv (July 2022)